FIT screening

Dikkedarmkanker, ook wel colorectaal carcinoom, is een veelvoorkomende ziekte onder voornamelijk ouderen. Het detecteren van dikke darmkanker in een vroeg stadium kan de overlevingskans van een patiënt aanzienlijk vergroten. Door gebruik te maken van een fecale immunochemische test (FIT) worden kleine hoeveelheden bloed (met behulp van antilichamen voor humaan hemoglobine) opgespoord in ontlastingsmonsters.

Sysmex biedt FIT-tests aan voor twee hoofdgroepen: grootschalig tests voor nationale of regionale bevolkingsonderzoeken, en symptomatische tests die hoofdzakelijk plaatsvinden in ziekenhuizen of klinische omgevingen. Lees hier meer over op onze FIT screening microsite

Clinical evaluation of Sysmex Inostics’ plasma NGS liquid biopsy technology to complement mammography when screening for early stage breast cancer presented at the 2018 ASCO annual meeting

Datum: 2018-07-11 Tags: Español, Press release, Noticias, España

Hamburg, Germany, 2018.05.31 – Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis, today announced that preliminary clinical results of a novel approach to screening early stage breast cancer will be presented at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 1-5, 2018. 

In this study, investigators utilized Sysmex Inostics’ highly sensitive plasma NGS technology based on the Safe-Sequencing System (Safe-SeqS) to confirm the results of mammography findings in early stage breast cancer patients.  While mammography is the current standard of care for breast cancer(BC) screening it is not always 100% informative, and in cases of abnormal findings, follow-up is performed via tissue biopsy to confirm/refute the presence of cancer. However, single site tissue analysis can be technically challenging, with false negatives due to tissue heterogeneity, failure to capture genomic profile of metastases, and limited tumor content.  Investigators analyzed circulating tumor DNA (ctDNA) in an attempt to represent more faithfully the genomic profile across and within sites of disease. 

Targeted NGS was performed for TP53 and PIK3CA - two of the most commonly mutated genes in breast cancer - on matched blood and tissue biopsy specimens collected from 56 women presenting with BIRADS 4c/5 mammography results and subsequent diagnosis of primary breast cancer.  Plasma NGS revealed mutations in either or both PIK3CA and TP53 in 10 of 29 patients, with 4 mutations detected in the plasma that were not identified in the tissue. The investigators concluded that mutations in ctDNA can be readily detected using a highly sensitive plasma sequencing method in breast cancer patients at mammography, suggesting that early ctDNA testing can provide critical clinical information that may improve patient diagnosis.

As Dr. Emilio Alba, Principal Investigator and UGC Medical Oncology Director at H. Regional Univ. and Hospital Virgen de la Victoria of Malaga commented on the findings, “Importantly, these results show value for the complementary assessment of plasma and tissue genetic alterations to accompany abnormal mammography findings in order to more accurately characterize the disease status of early stage breast cancer patients.  Clearly, mutations in ctDNA can be readily detected using a highly sensitive and focused plasma sequencing method at mammography and these promising findings open the possibility of improving the diagnosis of early-stage breast cancer patients in routine care.  We look forward to further evaluating the power of highly sensitive plasma NGS testing to gain insight into clonal diversity/expansion, monitor recurrence, guide treatment decisions, and evaluate therapy efficacy.”


Presentation Details (all times local):

  • Monday June 4, 1:15 to 4:45 PM, Hall A, Poster Session Category: Tumor Biology; Subcategory: Molecular Diagnostics and Imaging; Board #186; Abstract No. 12073. Plasma sequencing of ctDNA in early stage breast cancer as part of the screening process.


About Plasma Safe-Sequencing

Sysmex Inostics’ highly-sensitive Plasma Safe-Sequencing assays target a wide variety of genetic alterations in cell-free tumor DNA to support therapy selection, detection of emergent mutations, and assessment of drug response.  Plasma Safe-Sequencing panels can be custom designed to target the tumor of interest in order to ensure high sensitivity at optimal cost.


About Sysmex Inostics

Sysmex Inostics, a subsidiary of Sysmex Corporation, is a molecular diagnostic company whose core competency is mutation detection utilizing highly sensitive technologies such as BEAMing and Plasma Safe-Sequencing. Sysmex Inostics is a trusted partner to leading pharmaceutical companies, advancing their efforts to bring the most effective personalized cancer therapies to global markets.

With BEAMing and Plasma Safe-Sequencing being some of the most sensitive technologies available today for the detection of tumor-specific somatic mutations in blood samples, Sysmex Inostics’ services are readily available to support clinical trials and research in oncology.  In addition, OncoBEAM™ tests are available today through a CLIA-certified laboratory for routine clinical analysis. 

Sysmex Inostics’ headquarters and GCP Service Laboratory are located in Hamburg Germany; Sysmex Inostics’ Commercial Offices and CLIA-certified and GCP Clinical Laboratory is located in Baltimore, Maryland.  For more information on Plasma Safe-Sequencing and OncoBEAM™ blood testing, please visit or email .

Terug naar lijst
Enjoy our Media Centre
  • All
  • Documents
  • Podcast
  • Beelden
  • Video's
See our library of smears
Learn more about our concept
Growing your knowledge Visit our Academy
Sysmex XN – TAILORING YOUR HAEMATOLOGY See the scalability of XN
See our library of smears
Growing your knowledge Visit our Academy
Sysmex XN – TAILORING YOUR HAEMATOLOGY See the scalability of XN